• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ypT分类不影响淋巴结阴性胃癌的总生存期。

The ypT category does not impact overall survival in node negative gastric cancer.

作者信息

Ikoma Naruhiko, Hofstetter Wayne L, Estrella Jeannelyn S, Das Prajnan, Minsky Bruce D, Fournier Keith F, Mansfield Paul F, Ajani Jaffer A, Badgwell Brian D

机构信息

Departments of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Department Cardiac and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

J Surg Oncol. 2018 Jun;117(8):1721-1728. doi: 10.1002/jso.25081. Epub 2018 Jun 27.

DOI:10.1002/jso.25081
PMID:29949666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7703861/
Abstract

BACKGROUND

Although the eighth-edition American Joint Committee on Cancer (AJCC) gastric cancer staging system created ypTNM staging for patients who underwent preoperative therapy, the ideal ypTNM grouping is unknown. We sought to investigate risk factors for OS in ypT0-3N0M0 gastric cancer.

METHODS

From an institutional database of The University of Texas MD Anderson Cancer Center and the National Cancer Database (NCDB), we identified patients with ypT0-3N0M0 gastric adenocarcinoma who underwent R0 gastrectomy after chemotherapy or chemoradiation during 1995-2015 (MD Anderson) or 2006-2014 (NCDB).

RESULTS

The study included 175 MD Anderson and 3200 NCDB patients. By multivariable analysis, ypT category was not associated with OS (hazard ratio [HR] for ypT3 vs ypT1: MD Anderson, 0.83 [95% CI, 0.36-1.92], P = 0.669; NCDB, 0.96 [95% CI, 0.85-1.08], P = 0.472). cN-positive disease was not associated with OS in the MD Anderson cohort (HR, 0.96 [95% CI, 0.55-1.67]; P = 0.873) but was weakly associated with shorter OS in the NCDB cohort (HR, 1.11 [95% CI, 1.01-1.21]; P = 0.031).

CONCLUSIONS

The ypT category does not impact OS in ypT0-3N0M0 gastric cancer. The impact of cN status on OS appeared limited. These findings should be considered in future systems of post-neoadjuvant pathologic staging.

摘要

背景

尽管美国癌症联合委员会(AJCC)第八版胃癌分期系统为接受术前治疗的患者创建了ypTNM分期,但理想的ypTNM分组尚不清楚。我们试图研究ypT0-3N0M0期胃癌患者总生存期(OS)的危险因素。

方法

从德克萨斯大学MD安德森癌症中心的机构数据库和国家癌症数据库(NCDB)中,我们确定了在1995 - 2015年(MD安德森)或2006 - 2014年(NCDB)期间接受化疗或放化疗后行R0胃切除术的ypT0-3N0M0期胃腺癌患者。

结果

该研究纳入了175例MD安德森癌症中心的患者和3200例NCDB的患者。通过多变量分析,ypT分类与总生存期无关(MD安德森癌症中心,ypT3与ypT1相比的风险比[HR]为0.83[95%CI,0.36 - 1.92],P = 0.669;NCDB,HR为0.96[95%CI,0.85 - 1.08],P = 0.472)。在MD安德森队列中,cN阳性疾病与总生存期无关(HR,0.96[95%CI,0.55 - 1.67];P = 0.873),但在NCDB队列中与较短的总生存期弱相关(HR,1.11[95%CI,1.01 - 1.21];P = 0.031)。

结论

ypT分类对ypT0-3N0M0期胃癌的总生存期没有影响。cN状态对总生存期的影响似乎有限。这些发现应在未来的新辅助治疗后病理分期系统中予以考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29bb/7703861/700b0c5069d7/nihms-1646358-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29bb/7703861/700b0c5069d7/nihms-1646358-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29bb/7703861/700b0c5069d7/nihms-1646358-f0001.jpg

相似文献

1
The ypT category does not impact overall survival in node negative gastric cancer.ypT分类不影响淋巴结阴性胃癌的总生存期。
J Surg Oncol. 2018 Jun;117(8):1721-1728. doi: 10.1002/jso.25081. Epub 2018 Jun 27.
2
Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy.新辅助化疗和 D2 淋巴结清扫术后胃腺癌分期系统的建立与验证。
Br J Surg. 2019 Aug;106(9):1187-1196. doi: 10.1002/bjs.11181. Epub 2019 Jun 13.
3
Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching.术前放化疗比单独化疗更能频繁诱导胃癌原发灶完全缓解:基于 2006-2014 年国家癌症数据库的倾向评分匹配分析。
Gastric Cancer. 2018 Nov;21(6):1004-1013. doi: 10.1007/s10120-018-0832-z. Epub 2018 May 5.
4
Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.美国淋巴结分期对胃癌辅助治疗选择的影响:一项倾向评分匹配分析
Ann Surg. 2016 Feb;263(2):298-305. doi: 10.1097/SLA.0000000000001360.
5
Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved.胃癌患者的淋巴结降期:如果达到 ypN0,则有较好的生存获益。
Ann Surg Oncol. 2018 Jul;25(7):2012-2017. doi: 10.1245/s10434-018-6471-0. Epub 2018 May 10.
6
Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.淋巴结比率在选择接受辅助治疗的胃癌切除患者中的影响。
Surgery. 2017 Aug;162(2):285-294. doi: 10.1016/j.surg.2017.03.023. Epub 2017 May 31.
7
Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy.术前治疗后胃癌患者美国癌症联合委员会第 8 版分期系统的评估。
Gastric Cancer. 2018 Jan;21(1):74-83. doi: 10.1007/s10120-017-0743-4. Epub 2017 Jun 22.
8
ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system.中国胃癌人群新辅助化疗后 ypTNM 分期:对 AJCC 第八版癌症分期系统预后价值的评估。
Gastric Cancer. 2018 Nov;21(6):977-987. doi: 10.1007/s10120-018-0830-1. Epub 2018 May 10.
9
No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database.胃贲门癌患者新辅助化疗与新辅助放化疗生存无差异:来自国家癌症数据库的当代观点。
Dig Surg. 2020;37(3):249-257. doi: 10.1159/000501678. Epub 2019 Jul 24.
10
Adjuvant Therapy is Associated with Improved Survival in pT1N1 Gastric Cancer in a Heterogeneous Western Patient Population.辅助治疗与异质西方患者人群中 pT1N1 胃癌的生存改善相关。
Ann Surg Oncol. 2019 Jan;26(1):167-176. doi: 10.1245/s10434-018-6995-3. Epub 2018 Nov 12.

引用本文的文献

1
Optimal response population after neoadjuvant therapy for patients with locally advanced gastric cancer: A multicenter study.局部晚期胃癌患者新辅助治疗后的最佳反应人群:一项多中心研究。
Chin J Cancer Res. 2025 Apr 30;37(2):174-186. doi: 10.21147/j.issn.1000-9604.2025.02.05.
2
A novel ypN-TRG staging system for gastric cancer patients after neoadjuvant therapy based on the metro-ticket paradigm: a multicenter and large sample retrospective analysis.一种基于地铁票模式的新型胃癌新辅助治疗后ypN-TRG分期系统:多中心大样本回顾性分析
Gastric Cancer. 2025 May;28(3):465-477. doi: 10.1007/s10120-025-01586-x. Epub 2025 Feb 7.
3

本文引用的文献

1
Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014.美国胃癌患者术前化疗使用中的种族差异:基于国家癌症数据库的 2006-2014 年数据分析。
Cancer. 2018 Mar 1;124(5):998-1007. doi: 10.1002/cncr.31155. Epub 2018 Feb 2.
2
Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography.术前治疗患者选择中胃癌分期的术前准确性:种族可能影响内镜超声检查的准确性。
J Gastrointest Oncol. 2017 Dec;8(6):1009-1017. doi: 10.21037/jgo.2017.04.04.
3
Characterizing Patients with ypT0N1 Gastric Adenocarcinoma Within the AJCC Staging System.
在AJCC分期系统中对ypT0N1胃腺癌患者进行特征描述。
Ann Surg Oncol. 2025 Mar;32(3):2122-2128. doi: 10.1245/s10434-024-16408-0. Epub 2024 Dec 29.
4
Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma.胃食管交界腺癌的独立分期分类
Cancers (Basel). 2023 Oct 25;15(21):5137. doi: 10.3390/cancers15215137.
5
Trends of Oncological Quality of Robotic Gastrectomy for Gastric Cancer in the United States.美国机器人胃癌切除术的肿瘤学质量趋势
World J Oncol. 2023 Oct;14(5):371-381. doi: 10.14740/wjon1657. Epub 2023 Sep 20.
6
Adjuvant chemotherapy may be unnecessary for ypT0-2N0 gastric cancer patients after neoadjuvant chemotherapy and curative gastrectomy.对于接受新辅助化疗及根治性胃切除术后的ypT0-2N0期胃癌患者,辅助化疗可能并无必要。
Chin Med J (Engl). 2023 Aug 20;136(16):2002-2004. doi: 10.1097/CM9.0000000000002682. Epub 2023 Jun 26.
7
Revisiting the 8th AJCC system for gastric cancer: A review on validations, nomograms, lymph nodes impact, and proposed modifications.重新审视第八版美国癌症联合委员会(AJCC)胃癌分期系统:关于验证、列线图、淋巴结影响及修订建议的综述
Ann Med Surg (Lond). 2022 Feb 25;75:103411. doi: 10.1016/j.amsu.2022.103411. eCollection 2022 Mar.
8
The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy.新辅助化疗治疗的胃腺癌患者术后淋巴结比率的预后价值
Cureus. 2021 Apr 22;13(4):e14639. doi: 10.7759/cureus.14639.
9
Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer.术前治疗方案影响胃癌患者淋巴结降期的发生率及意义。
J Gastric Cancer. 2020 Sep;20(3):313-327. doi: 10.5230/jgc.2020.20.e29. Epub 2020 Sep 17.
10
Tumor Regression Grade in Gastric Cancer After Preoperative Therapy.胃癌术前治疗后的肿瘤退缩分级
J Gastrointest Surg. 2021 Jun;25(6):1380-1387. doi: 10.1007/s11605-020-04688-2. Epub 2020 Jun 15.
Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy.
术前治疗后胃癌患者美国癌症联合委员会第 8 版分期系统的评估。
Gastric Cancer. 2018 Jan;21(1):74-83. doi: 10.1007/s10120-017-0743-4. Epub 2017 Jun 22.
4
Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.《美国癌症联合委员会(AJCC)/国际抗癌联盟(UICC)第8版分期手册中食管癌和食管胃交界癌新辅助病理分期(ypTNM)的推荐》
Dis Esophagus. 2016 Nov;29(8):906-912. doi: 10.1111/dote.12538.
5
Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.食管癌与食管胃交界癌:第八版分期指南
J Thorac Oncol. 2017 Jan;12(1):36-42. doi: 10.1016/j.jtho.2016.10.016. Epub 2016 Oct 31.
6
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.胃癌临床实践指南(NCCN 肿瘤学版) 2016 年第 3 版
J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312. doi: 10.6004/jnccn.2016.0137.
7
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.ypN0:如何实现有那么重要吗?食管癌的淋巴结降期
Ann Surg Oncol. 2016 Dec;23(Suppl 5):998-1004. doi: 10.1245/s10434-016-5440-8. Epub 2016 Aug 1.
8
Tumor regression grade in gastric cancer: Predictors and impact on outcome.胃癌中的肿瘤消退分级:预测因素及其对预后的影响。
J Surg Oncol. 2016 Sep;114(4):434-9. doi: 10.1002/jso.24307. Epub 2016 May 20.
9
Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database.新辅助化疗对可切除胃癌围手术期结局的使用情况及影响趋势:来自美国外科医师学会国家癌症数据库的证据
Surgery. 2016 Apr;159(4):1099-112. doi: 10.1016/j.surg.2015.11.004. Epub 2015 Dec 17.
10
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.可切除胃食管腺癌的围手术期化疗与单纯手术比较:FNCLCC 和 FFCD 多中心 III 期试验。
J Clin Oncol. 2011 May 1;29(13):1715-21. doi: 10.1200/JCO.2010.33.0597. Epub 2011 Mar 28.